Search Bar & Filters
Found 6 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating the effects of APL-3007 combined with SyfovrePegcetacoplan APL-2 in patients with geographic atrophy caused by age-related macular degeneration AMD. This Phase 2 randomized, placebo-controlled study aims to assess the efficacy, safety, tolerability, and pharmacodynamics of these treatments in this eye condition. The study involves multiple centers and uses a masked design to ensure unbiased results. Participants will be assigned to one of three groups two receiving different doses or frequencies of APL-3007 in combination with pegcetacoplan APL-2, and one receiving a placebo along with pegcetacoplan APL-2. The study will evaluate the treatments given as multidose regimens. The treatments focus on complement C3 inhibition to potentially impact disease progression. Throughout the study, participants will undergo assessments including artificial intelligence-based imaging to measure retinal pigment epithelium lesion area and photoreceptor degeneration, safety evaluations through adverse event reporting and visual acuity tests, and blood tests to assess serum markers. These evaluations occur over 12 months to monitor changes from baseline. Participants involvement includes regular visits for these assessments, with the study tracking treatment effects and safety over the duration.
Actively Recruiting
Researchers are evaluating the similarity in effectiveness between ABP 938 8 mg and Aflibercept US 8 mg in people with neovascular age-related macular degeneration nAMD. The study aims to compare changes in best corrected visual acuity BCVA to understand how these treatments perform in improving vision for participants with this eye condition. Participants will be randomly assigned to receive intravitreal injections of either ABP 938 8 mg or Aflibercept 8 mg at the start of the study, Week 4, and Week 8. After these initial doses, participants will be regularly assessed starting at Week 16 to adjust injection schedules based on disease activity. The injections may then continue at intervals ranging from every 4 to 16 weeks up until the end of the study. Throughout the trial, participants will attend scheduled visits where vision tests like BCVA and imaging scans such as spectral-domain optical coherence tomography SD-OCT and fluorescein angiography FA will be performed. Researchers will monitor changes in vision, retinal fluid presence, lesion size, and safety outcomes including adverse events and immune responses. The study includes ongoing assessments of drug levels in blood samples, with participation lasting through multiple weeks with continuous monitoring.
Actively Recruiting
Researchers are evaluating the effectiveness of Selective Laser Trabeculoplasty SLT at low energy compared to standard energy for treating glaucoma and ocular hypertension. The study also aims to determine if repeating low energy SLT once a year can better prevent or delay the need for daily eye drop medications than waiting to repeat standard energy SLT until its effects wear off. This is a Phase 3 randomized trial focusing on treatment optimization for these eye conditions. Participants initially receive SLT treatment at standard energy, where energy levels are adjusted to produce champagne bubbles as a sign of effectiveness. At 12 months, eligible participants are randomly assigned to receive repeat SLT either annually with low energy or as needed with standard energy. The low energy SLT involves 100 treatment spots delivered at a lower energy level, adjusted as needed to maintain optimal response, while the standard energy SLT uses higher energy levels with similar adjustments. One arm of the initial low energy SLT was discontinued after interim analysis. Throughout the study, participants undergo regular eye pressure measurements and monitoring up to 48 months. Researchers measure outcomes such as survival without needing additional treatment at 12 and 48 months, average intraocular pressure IOP over time, and incidence of IOP spikes. Participants will attend scheduled visits for assessments and treatment as needed, with the total study duration lasting several years to evaluate long-term effects and safety.
Actively Recruiting
This research aims to evaluate patient and surgeon-reported outcomes for individuals undergoing blepharoplasty using a device called Ziplyft. The study focuses on measuring patient satisfaction with facial appearance and eyes, surgeon satisfaction and efficiency, bruising, eyelid symmetry, wound closure success with tissue adhesive, and case time. The study is interventional and monitors these outcomes over a 3-month period following the procedure. Participants will receive treatment with Ziplyft, a Class 1, 510k exempt device designed to remove excess unwanted eyelid skin through a novel surgical method. The procedure is performed once, followed by regular follow-up visits extending up to 3 months to assess various outcomes including the success of wound closure and improvements in eyelid appearance and symmetry. Throughout the study, participants will attend scheduled visits for evaluations that include patient and surgeon feedback, assessments of bruising and eyelid symmetry, and measurements related to wound healing and procedure efficiency. Researchers will track these factors from enrollment through the final visit at 3 months to understand the devices performance and participant satisfaction. Participants are also monitored for any adverse effects and are expected to comply with study instructions and follow-up visits during this time.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
This research study focuses on people who wear contact lenses but find it uncomfortable to wear them for long periods due to dry eye symptoms. The study aims to evaluate whether using Lacrifill regularly over a 2 to 3 month period can help people wear their contact lenses longer without discomfort and reduce signs and symptoms of dry eye. Lacrifill is a drug being studied for its potential to improve comfort for contact lens users with dry eye. Participants in this trial will use Lacrifill, a cross-linked hyaluronic acid derivative that temporarily blocks tear drainage to keep the eyes bathed in natural tears. This is a single-arm study without a comparison group, and the treatment will be used over 2 to 3 months. The study will monitor the effects of Lacrifill on dry eye symptoms and contact lens tolerability during this period. During the study, participants will be assessed through various questionnaires and clinical tests to measure dry eye signs, symptoms, and contact lens wear time. These include the CLDEQ-8 and OSDI questionnaires, tear break-up time, corneal staining, and Schirmers tear test. Safety and tolerability will be closely monitored throughout the study. The total participation time is about 2 to 3 months, with results focusing on changes in dry eye and contact lens comfort.